The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice

Antonio Salar, Corinne Haioun, Francesca G. Rossi, Ulrich Duehrsen, Ruth Pettengell, Hans E. Johnsen, Ulrich Jaeger, Gregor Verhoef, Matthias Schwenkglenks, Pamela Bacon, Kate Bendall, Pieternella J. Lugtenburg

Research output: Contribution to journalArticlepeer-review

Abstract

Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.

Original languageEnglish
Pages (from-to)548-553
Number of pages6
JournalLeukemia Research
Volume36
Issue number5
DOIs
Publication statusPublished - May 2012

Keywords

  • Diffuse large B-cell lymphoma
  • Febrile neutropenia
  • Granulocyte colony stimulating factor
  • R-CHOP-21
  • Relative dose intensity
  • Risk assessment

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: Findings from clinical practice'. Together they form a unique fingerprint.

Cite this